research Techniques d'épargne cutanée dans la chirurgie de la gynécomastie
Skin-sparing techniques in gynecomastia surgery lead to good chest results and high patient satisfaction with less scarring.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research Phytochemicals in the Management of Polycystic Ovary Syndrome, Endometriosis, and Menstrual Irregularities
Plant compounds may help manage PCOS, endometriosis, and menstrual issues.
research Green Tea as a Supportive Therapy for PCOS: Evaluating Its Impact on Symptom Relief
Green tea may help relieve PCOS symptoms, but more research is needed.
research Efficacy of Cosmerna ARI in Improving Androgenetic Alopecia in Europeans: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial over 6 months
Cosmerna ARI effectively reduces hair loss and increases hair density in Europeans with androgenetic alopecia.
research A cross-specialty expert opinion on the management of hair loss in gynaecological and endocrinological disorders in Indian patients
A multidisciplinary approach is crucial for effectively managing hair loss linked to endocrine and gynecological disorders.
research Elevated serum chromogranin A levels are independently associated with metabolic and inflammatory disturbances in polycystic ovary syndrome
High chromogranin A levels are linked to obesity and inflammation in polycystic ovary syndrome.
research Comparative Study of Myocardial Biomarkers Among Women with and Without Polycystic Ovarian Syndrome (Pcos) in Nigeria
Women with PCOS in Nigeria have higher heart risk markers, needing early heart health checks.
research Real-world pharmacovigilance insights into drug-induced risk of alopecia
64 drugs can cause hair loss, needing better monitoring and updated labels.
research Farmácia Boa Hora - Porto
Minoxidil and spironolactone can improve hair growth, but responses vary and side effects are common.
research Alopecia induced by CDK 4/6 Inhibitors and its Impact on the Quality of Life of Patients with advanced Breast cancer
Alopecia from CDK 4/6 inhibitors worsens quality of life in breast cancer patients.